TY  - JOUR
AU  - Wang, Justin Z
AU  - Landry, Alexander P
AU  - Raleigh, David R
AU  - Sahm, Felix
AU  - Walsh, Kyle M
AU  - Goldbrunner, Roland
AU  - Yefet, Leeor S
AU  - Tonn, Jörg C
AU  - Gui, Chloe
AU  - Ostrom, Quinn T
AU  - Barnholtz-Sloan, Jill
AU  - Perry, Arie
AU  - Ellenbogen, Yosef
AU  - Hanemann, C Oliver
AU  - Jungwirth, Gerhard
AU  - Jenkinson, Michael D
AU  - Tabatabai, Ghazaleh
AU  - Mathiesen, Tiit I
AU  - McDermott, Michael W
AU  - Tatagiba, Marcos
AU  - la Fougère, Christian
AU  - Maas, Sybren L N
AU  - Galldiks, Norbert
AU  - Albert, Nathalie L
AU  - Brastianos, Priscilla K
AU  - Ehret, Felix
AU  - Minniti, Giuseppe
AU  - Lamszus, Katrin
AU  - Ricklefs, Franz L
AU  - Schittenhelm, Jens
AU  - Drummond, Katharine J
AU  - Dunn, Ian F
AU  - Pathmanaban, Omar N
AU  - Cohen-Gadol, Aaron A
AU  - Sulman, Erik P
AU  - Tabouret, Emeline
AU  - Le Rhun, Emelie
AU  - Mawrin, Christian
AU  - Moliterno, Jennifer
AU  - Weller, Michael
AU  - Bi, Wenya
AU  - Gao, Andrew
AU  - Yip, Stephen
AU  - Niyazi, Maximilian
AU  - Aldape, Kenneth
AU  - Wen, Patrick Y
AU  - Short, Susan
AU  - Preusser, Matthias
AU  - Nassiri, Farshad
AU  - Zadeh, Gelareh
TI  - Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients
JO  - Neuro-Oncology
VL  - 26
IS  - 10
SN  - 1522-8517
CY  - Oxford
PB  - Oxford Univ. Press
M1  - FZJ-2025-00580
SP  - 1742 - 1780
PY  - 2024
AB  - Meningiomas are the most common primary intracranial tumors in adults and are increasing in incidence due to the aging population and increased access to neuroimaging. While most exhibit nonmalignant behavior, a subset of meningiomas are biologically aggressive and are associated with treatment resistance, resulting in significant neurologic morbidity and even mortality. In recent years, meaningful advances in our understanding of the biology of these tumors have led to the incorporation of molecular biomarkers into their grading and prognostication. However, unlike other central nervous system (CNS) tumors, a unified molecular taxonomy for meningiomas has not yet been established and remains an overarching goal of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official World Health Organization (cIMPACT-NOW) working group. Additionally, clinical equipoise still remains on how specific meningioma cases and patient populations should be optimally managed. To address these existing gaps, members of the International Consortium on Meningiomas including field-leading experts, have prepared this comprehensive consensus narrative review directed toward clinicians, researchers, and patients. Included in this manuscript are detailed overviews of proposed molecular classifications, novel biomarkers, contemporary treatment strategies, trials on systemic therapies, health-related quality-of-life studies, and management strategies for unique meningioma patient populations. In each section, we discuss the current state of knowledge as well as ongoing clinical and research challenges to road map future directions for further investigation.Keywords: extra-axial; meningioma; methylation; molecular; neurofibromatosis 2; nonmalignant; radiotherapy.
LB  - PUB:(DE-HGF)16
C6  - 38695575
UR  - <Go to ISI:>//WOS:001269694700001
DO  - DOI:10.1093/neuonc/noae082
UR  - https://juser.fz-juelich.de/record/1037247
ER  -